The Correct e- Mixtures (A fully validated EHR, the way forward) Brendan Delaney Guy’s and St Thomas’ Charity Chair in Primary Care Research.

Slides:



Advertisements
Similar presentations
Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Advertisements

CDM Registry Project Dr. Richard Lewanczuk Regional Medical Director Chronic Disease Management Capital Health.
Reduce Cost & Complexity Partner logo here Presenters Name (16pt) Presenters Title (14pt) Company/ (14pt) Manage and Deploy Applications using Virtualization.
Translational Research and Patient Safety in Europe TRANSFoRm: Vision of a learning healthcare system.
ELTSS Alignment to Nationwide Interoperability Roadmap DRAFT: For Stakeholder Consideration in response to public comment.
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
AHSN Digital Health Event, iHouse, Coventry Professor T.N. Arvanitis - 13/12/2013 Enabling clinical research in West Midlands: ePCRN, TRANSFoRm and CuRE.
AHCCCS/ASU Clinical Data Project March 17 th, 2009 Arizona Health Care Cost Containment Health System Medicaid Transformation Grant Program.
Linked2Safety Project (FP7-ICT – 5.3) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
Harnessing health data for patient and public benefit Professor Tjeerd van Staa HeRC
Translational Research and Patient Safety in Europe TRANSFoRm: Requirements analysis for the learning healthcare system.
Interoperability to Support a Learning Health System HL7 Learning Health Systems Workgroup.
© 2010 AT&T Intellectual Property. All rights reserved. AT&T, the AT&T logo and all other AT&T marks contained herein are trademarks of AT&T Intellectual.
The EHR-S FIM project plans to harmonize the EHR-S FM R2
EHR Clinical data repository and pharmacovigilance Suzanne Markel-Fox 12 October 2007.
Cancer Clinical Trial Suite (CCTS): An Introduction for Users A Tool Demonstration from caBIG™ Bill Dyer (NCI/Pyramed Research) June 2008.
Clinical Trials in the Age of Personalized Cancer Medicine: The Evolution of a More Efficient, Patient Focused Clinical Research System Session Chair:
1. Re-Use of Clinical Care and of Clinical Trial Data A Contract Research Organisation (CRO) point of view EuroRec Conference 2009 Sarajevo Selina Sibbald.
PHS / Department of General Practice Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Clinical Prediction Rules as a basis for.
A Model-Driven Approach to Interoperability and Integration in Systems of Systems Gareth Tyson Adel Taweel Steffen Zschaler Tjeerd Van Staa Brendan Delaney.
METU-SRDCEUROREC Meeting, Geneva, October 10, 2006 RIDE Overview Asuman Dogac Middle East Technical University Ankara, Turkey.
1 Networked PHR, a framework for personal health applications & services Anne Chapman, Senior Program Manager Personal Health Records, Intel.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
EHR stakeholder workshop – 11th October EHR integration for clinical research: Legal & Privacy issues Mats Sundgren – AstraZeneca Petra Wilson -
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
Topic 3A SEMANTIC INTEROPERABILITY: REUSE OF EHR DATA Mats Sundgren.
John McGeagh, PhD | NIHR CLAHRC West Collaboration for Leadership in Applied Health Research and Care The power and potential pitfalls of working with.
Bayesian approach to equivalence study of medical device 1 1.
S ecure A rchitecture F or E xchanging Health Information in Central Massachusetts Larry Garber, M.D. Peggy Preusse, R.N. June 9 th, 2005.
SAGE Nick Beard Vice President, IDX Systems Corp..
Sherri de Coronado Enterprise Vocabulary Services NCI Center for Bioinformatics and Information Technology March 11, 2009 A Terminology.
Introducing Novell ® Identity Manager 4 Insert Presenter's Name (16pt) Insert Presenter's Title (14pt) Insert Company/ (14pt)
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
TRANSFoRm A flexible zone model for data privacy and confidentiality in medical research Wolfgang Kuchinke 1,Christian Ohmann, 1 Evert-Ben van Veen 2,
1 CDC Health Information Exchange (HIE) Accelerating State-wide Public Health Situational Awareness in New York Through Health Information Exchanges August.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Presenter Title Organization
Track 11 Symposium 27 June :30 – 3:00 PM
Perspective on GCP Warning Letters
NewMind Network for Mental Health Technology
Molly Butler Auditor II Quality Associates, Inc.
Interactive Session: Presentation of Scenarios and Q&A
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
FirstPoint and FirstDoc Application of the DIA EDM Reference Model
Presenter Name Title Organization.
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
The HIPAA Privacy Rule and Research
Clinical and Translational Science Awards Program
Omnibus Care Plan (OCP) Care Coordination System
Presenter Name Title Organization.
UK Healthcare Text Analytics
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
William W. Gregory for the CIOMS MLG Exploratory Team Pfizer Inc
Presentation transcript:

The Correct e- Mixtures (A fully validated EHR, the way forward) Brendan Delaney Guy’s and St Thomas’ Charity Chair in Primary Care Research

Requirements of observational research Data description Cohort management Data quality Data linkage –Semantic interoperability –Privacy –Matching

Requirements of interventional research Feasibility –Simple via distributed search –Complex via CPRD Recruitment –Privacy requirements Data management –eSource Adverse Event Reporting

What tools exist currently Legacy systems –Electronic Health Record Systems –Web based data collection forms and CTDMS –Clinical trial administration systems Projects in pilot and deployment CPRD Observational research platform Wellcome Trust eLung and RetroPro ePCRN FP7 TRANSFoRm

OBSERVATIONAL RESEARCH PLATFORM AND INCIDENT CASE RECRUITMENT

CPRD A Primary care clinical data warehouse Vision EHR (~20%) 600 clinics out 2500 clinics in the UK (out of clinics) provides a good sample UK primary care data Expanding to other three UK eHR vendors –50-60% coverage of UK pop –More streamlined and daily updates –Linkage

eLUNG and RETROPRO eLUNG: antibiotics vs standard care for COPD exacerbation RETROPRO: comparative study of different types of statins Recruitment at point of care (LEPIS) Feasibility studies funded by HTA and Wellcome Trust

The Approach Local autonomous agents to identify potential participants and facilitate their recruitment Interactive agents: with the physician Non-intrusive to the physician healthcare process Can easily be dismissed but yet has memory of GP actions Standardised and vocabulary controlled Scalable and highly configurable

Agent-based Technology Autonomous provides configurable flexibility adaptive to user requirements non-intrusive behaviour Asynchronous automation agents self-update their knowledge/registry configure for performance needs

Overall Architecture GPRD warehouse CTMS CCS LEPIS SiS Workbench Clinical trial data management system LEPIS: Local Eligible Participant Identification Service CCS: Central Control Service

FEASIBILITY AND RECRUITMENT OF PREVALENT CASES

 Funded by National Institutes of Health ‘Roadmap’ Program – pilot.  Facilitates recruitment by establishing a secure distributed query process for eHRs to identify eligible subjects  Proof of concept interoperable clinical trial data management system for Primary Care  NIHR NSPCR, Wellcome Trust (CPRD, ALSPAC), HTA, EU FP7 The electronic Primary Care Research Network (ePCRN)

Confidentiality and data security  Confidentiality - for subjects not having consented to use of their data for research  Search reports only ‘counts’ - NO DATA is extracted  Subjects are flagged locally  Security  OGSA-DAI & GTK4(certificates and authorisation)

Define eligibility criteria

Define the clinical problem semantically

Define further clinical problems, drugs or vital signs

Count eligible community subjects

Research network director approval tool

ADVANCED OBSERVATIONAL PLATFORM AND EMBEDDED ELECTRONIC CASE REPORT FORMS

Existing methods of trial data management are limited  No standardization of electronic case report forms (CRFs), timelines etc.  No reusability of data elements  No standardization of data structures  No automatic linkage of data elements and data structures

TRANSFoRm Consortium

Aims of TRANSFoRm To develop methods, models, services, validated architectures and demonstrations to support: –Epidemiological research using GP records, including genotype-phenotype studies and other record linkages –Research workflow embedded in the EHR –Decision support for diagnosis 22

Type 2 DM study Question: Relationship between SNPs and response to oral T2DM medication Genotype-Phenotype record linkage study –Privacy model –Record linkage (browsing, selecting, extracting) –Data quality tool –Provenance tool 23

GORD Treatment study Question: Effectiveness of on-demand v continuous PPI RCT with event-initiated patient-related outcome measures –Trigger within EHR –Semantic Mediator –eCRF tool (embedded in EHR) 24

Overall Architecture Distributed Nodes Middleware (Distributed Infrastructure) End User Tools and Services Support Services

Data source or collection Care Zone Non-care Zone Primary data Secondary data in DB Data use Research Zone Compatible use incompatibl e use Identifyng data Private data Identifiable data Genetic data Medical data Non- identifiable Data controller: Different national definitions for personal data, sensitive data, controller / processor, re-use of data for scientific purpose research

eSource two models

Discussion Ongoing mainly EU-funded projects will provide a stream of innovations in: –Computable representations of study designs –Interoperability –Data quality –Privacy, security and provenance –Workflow

29 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.